Moderate

Lymphangioleiomyomatosis

cystic lung disease · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

LAM is a rare cystic lung disease affecting almost exclusively women of reproductive age, caused by proliferation of abnormal smooth-muscle-like cells with mTOR pathway activation. It presents with progressive dyspnoea, recurrent pneumothorax and chylous effusions, and can be sporadic or tuberous-sclerosis-associated.

Red flags

  • Recurrent or bilateral pneumothorax
  • Rapidly declining lung function
  • Large renal angiomyolipoma with bleeding risk
  • Chylothorax with nutritional compromise

Assessment

Differential diagnosis

  • Pulmonary Langerhans cell histiocytosis
  • Birt-Hogg-Dube syndrome
  • Emphysema
  • Lymphocytic interstitial pneumonia
  • Pneumocystis (cystic pattern)

Investigations

  • HRCT chest (diffuse thin-walled round cysts, uniform distribution)
  • Serum VEGF-D (elevated supports diagnosis non-invasively)
  • Lung function (obstructive pattern with low DLCO)
  • Screen for tuberous sclerosis and renal angiomyolipomas (abdominal imaging)
  • Assessment for chylous effusions and pneumothorax history

Management

  • Suspect in a woman with cystic lung disease, recurrent pneumothorax or chylothorax
  • Characterise the HRCT cyst pattern and assess extent
  • Measure serum VEGF-D to support a non-biopsy diagnosis where cysts are characteristic
  • Screen for tuberous sclerosis and abdominal angiomyolipomas
  • Assess physiology with lung function and walk testing
  • Start mTOR inhibitor therapy for impaired or declining lung function
  • Monitor lung function trajectory to guide therapy
  • Manage pneumothorax with a low threshold for definitive pleurodesis (high recurrence)
  • Avoid oestrogen-containing medication and counsel on pregnancy risks
  • Refer progressive disease for lung transplant assessment

Drugs & doses

Sirolimus titrated to trough 5-15 ng/mL (mTOR inhibitor) for declining lung function or chylous disease
Everolimus as an alternative mTOR inhibitor
Avoid oestrogen-containing contraceptives/HRT
Bronchodilators for the obstructive component where responsive

Disposition

Specialist / national LAM service; early pleurodesis for pneumothorax; transplant referral for advanced disease.

Complications & pitfalls

  • Recurrent pneumothorax
  • Chylous effusions / chylous ascites
  • Progressive respiratory failure
  • Renal angiomyolipoma haemorrhage

Exam pearls

  • An elevated serum VEGF-D with typical cysts can confirm LAM without lung biopsy
  • mTOR inhibitors (sirolimus) stabilise lung function and shrink angiomyolipomas
  • Pneumothorax recurrence is very high — favour early pleurodesis
  • Oestrogen may drive disease; avoid oestrogen-containing therapy

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.